MacroGenics, Inc.

MacroGenics develops, manufactures, and commercializes antibody-based therapeutics for cancer treatment. Their approved product is MARGENZA, an anti-HER2 receptor antagonist. The companys pipeline includes product candidates targeting B7-H3, PD-1, and other immune checkpoints. Additional products in development target solid tumors, hematologic malignancies, and autoimmune indications. MacroGenics collaborates with Incyte Corporation, Zai Lab Limited, I-Mab Biopharma, and Janssen Biotech. The company was founded in 2000 and is headquartered in Rockville, Maryland.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

1.5 USD

Potential

-100%

Strengths

Price to book ratio (0.88) is lower than the sector mean (24.44).
EV/EBITDA (0.47) is lower than the sector mean (85.60).
EV/EBIT (0.67) is lower than the sector mean.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (1.55) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	0.5
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	1.6